Adding pembrolizumab to docetaxel does not appreciably affect efficacy outcomes among patients who received prior treatment for metastatic castration-resistant prostate cancer (mCRPC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback